メインナビゲーションにスキップ 検索にスキップ メインコンテンツにスキップ

Trends and efficacy of interferon-free anti–hepatitis C virus therapy in the region of high prevalence of elderly patients, cirrhosis, and hepatocellular carcinoma: A real-world, nationwide, multicenter study of 10 688 patients in Japan

  • Hidenori Toyoda
  • , Masanori Atsukawa
  • , Haruki Uojima
  • , Akito Nozaki
  • , Hideyuki Tamai
  • , Koichi Takaguchi
  • , Shinichi Fujioka
  • , Makoto Nakamuta
  • , Toshifumi Tada
  • , Satoshi Yasuda
  • , Makoto Chuma
  • , Tomonori Senoh
  • , Akemi Tsutsui
  • , Naoki Yamashita
  • , Atsushi Hiraoka
  • , Kojiro Michitaka
  • , Toshihide Shima
  • , Takehiro Akahane
  • , Ei Itobayashi
  • , Tsunamasa Watanabe
  • Hiroki Ikeda, Etsuko Iio, Shinya Fukunishi, Toru Asano, Yoshihiko Tachi, Tadashi Ikegami, Kunihiko Tsuji, Hiroshi Abe, Keizo Kato, Shigeru Mikami, Hironao Okubo, Noritomo Shimada, Toru Ishikawa, Yoshihiro Matsumoto, Norio Itokawa, Taeang Arai, Akihito Tsubota, Katsuhiko Iwakiri, Yasuhito Tanaka, Takashi Kumada

研究成果: ジャーナルへの寄稿 › 学術論文 › 査読

27   !!Link opens in a new tab 被引用数 (Scopus)

抄録

Background. We investigated changes in patient characteristics, rate of sustained virologic response (SVR), and factors associated with SVR after anti-hepatitis C virus (HCV) therapy with direct-acting antiviral (DAA) regimens in real-world practice in Japan, where patients with HCV are characterized by older age and high prevalence of cirrhosis and hepatocellular carcinoma (HCC). Methods. Changes in patient characteristics and SVR rates were evaluated from medical records among 10 688 patients who started interferon (IFN)-free DAA therapy between September 2014 and June 2018 in a nationwide, multicenter study. Factors associated with failure of SVR were analyzed. In particular, effects of cirrhosis or history of HCC on SVR were assessed by exact matching. Results. Patient age was becoming younger and baseline liver fibrosis was becoming milder over time. Overall SVR rate was 95.4%. The SVR rates increased over time in patients without a history of IFN-free DAA therapy. Multivariate analysis revealed that cirrhosis was unfavorably associated with achievement of SVR in both patients with genotype 1 (odds ratio, 1.68; 95% confidence interval [CI], 1.27–2.21) and genotype 2 (odds ratio, 1.69; 95% CI, 1.01–2.78). Comparisons after exact matching showed that the SVR rate was significantly lower in patients with cirrhosis than without it, whereas patients with and without a history of HCC had similar SVR rates. Conclusions. Background characteristics of patients who undergo IFN-free DAA therapy are changing in Japan. Patients without a history of IFN-free DAA therapy have high SVR rates. Exact matching confirmed that cirrhosis significantly influences the achievement of SVR in real-world settings.

本文言語英語
ジャーナルOpen Forum Infectious Diseases
巻6
号5
DOI
出版ステータス出版済み - 01-05-2019
外部発表はい

UN SDG

この成果は、次の持続可能な開発目標に貢献しています

  1. SDG 3 - すべての人に健康と福祉を
    SDG 3 すべての人に健康と福祉を

All Science Journal Classification (ASJC) codes

  • 腫瘍学
  • 感染症

フィンガープリント

「Trends and efficacy of interferon-free anti–hepatitis C virus therapy in the region of high prevalence of elderly patients, cirrhosis, and hepatocellular carcinoma: A real-world, nationwide, multicenter study of 10 688 patients in Japan」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル